Hydromorphone IV Administration: Dilution Requirements
Yes, hydromorphone should be diluted and administered slowly when given intravenously. The FDA label explicitly states that IV hydromorphone "should be given very slowly" over at least 2 to 3 minutes, and rapid IV injection increases the risk of hypotension and respiratory depression 1.
Administration Guidelines
Intravenous Route
- Dilution is recommended for IV push administration
- Administer slowly over 2-3 minutes minimum depending on the dose 1
- Rapid IV injection significantly increases risk of:
- Hypotension
- Respiratory depression 1
Dosing by Route
IV Administration:
- Initial dose: 0.2-1 mg every 2-3 hours
- Must be given slowly over at least 2-3 minutes 1
Subcutaneous/Intramuscular:
- Initial dose: 1-2 mg every 2-3 hours
- No specific dilution requirements mentioned for these routes 1
Key Safety Considerations
Critical Warning: The FDA label specifically emphasizes that "Rapid intravenous injection of opioid analgesics increases the possibility of side effects such as hypotension and respiratory depression" 1. This makes slow administration over 2-3 minutes mandatory, not optional.
Preparation Notes
- Inspect for particulate matter and discoloration before administration
- Slight yellowish discoloration may develop but does not indicate loss of potency
- Physically compatible and chemically stable for at least 24 hours at 25°C when protected from light in most common large volume parenteral solutions 1
Concentrated Solutions
For subcutaneous infusions requiring high doses, hydromorphone can be prepared in concentrated solutions (10 mg/mL, 20 mg/mL, 50 mg/mL, and 100 mg/mL) and remains stable for 28 days in both normal saline and D5W 2. However, this applies primarily to continuous subcutaneous infusions, not IV bolus administration.
Common Pitfall
Do not confuse the concentrated formulations used for subcutaneous infusions with IV bolus dosing. IV bolus doses are much smaller (0.2-1 mg range) and must always be given slowly over 2-3 minutes to prevent cardiovascular and respiratory complications 1.